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INTRODUCTION
HLA-specific antibodies have been considered a significant 
barrier to successful kidney transplantation since this was 
first recognized in 1969.1 In the mid-1980s, pretransplant 
antibody removal, or desensitization, was pioneered to 
overcome this barrier,2 but these have tended to be high-
risk transplants with inferior outcomes. Moreover, in recent 
years, there has been a downward trend of HLA antibody 
Kidney Transplantation
Background. HLA incompatible renal transplantation still remains one of best therapeutic options for a subgroup of patients 
who are highly sensitized and difficult to match but not much is known about its long-term graft and patient survival. Methods. 
One hundred thirty-four HLA incompatible renal transplantation patients from 2003 to 2018 with a median follow of 6.93 y were 
analyzed retrospectively to estimate patient and graft survivals. Outcomes were compared with groups defined by baseline 
crossmatch status and the type and timings of rejection episodes. Results. The overall patient survival was 95%, 90%, and 
81%; and graft survival was 95%, 85%, and 70% at 1, 5, and 10 y, respectively. This was similar to the first-time deceased donor 
transplant cohort. The graft survival for pretreatment cytotoxic-dependent crossmatch (CDC) positive crossmatch group was 
significantly low at 83%, 64%, and 40% at 1, 5, and 10 y, respectively, compared with other groups (Bead/CDC, P = 0.007; 
CDC/Flow, P = 0.001; and microbead assay/flow cytometry crossmatch, P = 0.837), although those with a low CDC titer 
(<1 in 2) have comparable outcomes to the CDC negative group. Female patients in general fared worse in both patient and 
graft survival outcomes in each of the 3 groups based on pretreatment crossmatch, although this did not reach statistical 
significance. Antibody-mediated rejection was the most frequent type of rejection with significant decline in graft survival 
by 10 y when compared with no rejection (P < 0.001). Rejection that occurred or continued to occur after the first 2 wk of 
transplantation caused a significant reduction in graft survivals (P < 0.001), whereas good outcomes were seen in those with 
a single early rejection episode. Conclusions. One-, 5-, and 10-y HLA incompatible graft and patient survival is compa-
rable to deceased donor transplantation and can be further improved by excluding high-CDC titer cases. Antibody-positive 
female patients show worse long-term survival. Resolution of early rejection is associated with good long-term graft survival.
(Transplantation Direct 2021;7: e732; doi: 10.1097/TXD.0000000000001183. Published online 19 July, 2021.)
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incompatible (HLAi) renal transplantation worldwide. 
In the United Kingdom, although approximately 40% of 
patients on the transplant waiting list are sensitized with 
HLA-specific antibodies, only 1.5% of the kidney trans-
plantations performed last year were HLAi renal transplan-
tations.3 The reason for the global decrease in HLAi kidney 
transplantation is the concomitant increase in the paired 
kidney exchange (PKE) programs and the changes in the 
local allocation policies.4,5 Nevertheless, there is an ongoing 
requirement for HLAi transplantation in patients wherein 
finding a compatible donor through PKE is difficult. For 
these highly sensitized patients, desensitization could be 
considered via a combined approach wherein the recipi-
ents are offered a lower immunologic risk donor through 
the PKE or directly from their potential donors after risk 
stratification.6 Moreover, with the increase in fast track and 
extended criteria donors, it is likely that more patients will 
be sensitized in the coming years because of the reduced 
longevity of these kidneys and lower levels of HLA match-
ing,7 thus potentially increasing the need for HLAi trans-
plantation. Therefore, it becomes important to determine 
the benefits or detriment of such transplantations so that 
we can use this appropriately to optimize patient care.
Studies have reported an increase in patient survival with 
HLAi renal transplantation in comparison to patients remain-
ing on the waiting list or on dialysis.8,9 However, a recent study 
from the United Kingdom did not show any survival benefit in 
patients undergoing HLAi in comparison to those who remain 
on dialysis.10 Many studies have also shown reasonable suc-
cess in short- and medium-term outcomes in graft survival in 
HLAi renal transplantation.11,12 Advances in antibodies detec-
tion and screening, HLA typing, and desensitization of patients 
have aided in curtailing the risk associated with HLAi renal 
transplants.13 Despite this, graft rejection remains a major 
obstacle in achieving more successful long-term outcomes in 
HLAi renal transplantations, which is further compounded by 
the lack of effective treatment for antibody-mediated rejection 
(AMR).14 There is, however, a lack of published on long-term 
(10 or more y) outcome data for HLAi kidney transplantation. 
We now have completed sufficient cases to be able to show 
10-y patient and graft survival data and identify key factors 
that determine long-term outcomes.
MATERIALS AND METHODS
Patients
A retrospective study was conducted at the University 
Hospitals Coventry and Warwickshire (UHCW) NHS Trust, 
which is a UK tertiary international referral center for HLAi 
transplants. The study was approved by the Coventry University 
Ethical committee and the UHCW Research and Development. 
Patients who underwent HLAi renal transplantation between 
2003 and 2018 were included. Table  1 lists the key charac-
teristics of the study population. These patients were referred 
from various centers in the United Kingdom and Ireland and 
were transferred back once stable posttransplant. All relevant 
clinical data of patients were collated from UHCW and refer-
ral centers, whereas all immunologic and histocompatibility-
related data were collated from NHS Blood and Transplant 
Centre, Birmingham. We also compared the overall patient 
and graft survival data of the HLAi study cohort with (i) first-
time deceased donor renal transplant, UK cohort, (ii) first-time 
deceased donor transplant, (iii) UHCW (our center) cohort, 
and (iv) the standard live donor transplant of UHCW cohort.
Patients sensitized to HLA antigens were selected for anti-
body incompatible transplantation if they had reactivity with 
donor HLA antigens measured by cytotoxic-dependent cross-
match (CDC), flow cytometry crossmatches (FC), or micro-
bead assay (Bead). Patients who had ABO incompatibility or 
had combined HLAi and ABOi transplants were excluded.
Pretransplant patients were typically treated with 5 alter-
nate day sessions of double filtration plasmapheresis (DFPP) 
with the aim of achieving negative flow crossmatch at the time 
of surgery. In some cases, depending on the starting levels of 
DSA, fewer or more sessions of DFPP were administered and 
the transplant was performed in the presence of FC-positive 
crossmatch.12,15
Immunosuppression Protocols
Immunosuppression consisted of mycophenolate mofetil, 
tacrolimus, and prednisolone as previously described12 and 
TABLE 1.
Patient characteristics
Patient characteristics HLAi cohort
Total number of patients 134
Gender, n (%)  
 Female 82 (61.2)
 Male 52 (38.8)
Mean age at time of transplantation, mean ± SD 42.93 ± 11.52
Median follow-up time in y, median ± SD 6.93 ± 3.33
Donor-specific antibodies, n (%)  
 Class I HLA 52 (38.8)
 Class II HLA 41 (30.6)
 Class I + II HLA 41 (30.6)
Crossmatch, n (%)  
 Bead positive 47 (35.1)
 FC positive 64 (47.8)
 CDC positive 23 (17.2)
Transplantation type, n (%)  
 Living donor transplantation 118 (88.1)
 Deceased donor transplantation 16 (12.0)
Comorbidities  
 Yes, n (%) 61 (45.5)
  Hypertension, n 8
  Hypotension, n 12
  Obesity, n 4
  Diabetes, n 3
  Others, n 34
 No, n (%) 73 (55.5)
Number of previous transplants, n (%)  
 0 51 (38.1)
 1 61 (45.5)
 2 15 (11.2)
 3 7 (5.2)
aTreatment approach, n  
 OKT3 8
 ATG 35
 IVIG 6 (including 2 preop)
 Rituximab 2 (preop)
 Campath 3
aPatients with >1 treatment for rejection.
ATG, antithymocyte globulin; Bead, microbead assay; CDC, cytotoxic-dependent crossmatch; FC, 
flow cytometry crossmatch; HLAi, HLA antibody incompatible; OKT3, muromomab-CD3.
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methylprednisolone 500 mg was given as a single intravenous 
dose intraoperatively. Two doses of basiliximab 20 mg were 
given, at days 0 and 4. Posttransplant serum samples for anti-
body analysis were taken daily for the first 2 wk and then 3 
times a week for the next 2 wk.
Treatment of Rejection
Rejection was diagnosed by renal biopsy or clinically if 
there was rapid onset of oliguria with a rise in both serum cre-
atinine and in DSA levels. During the initial few years of our 
AiT program, rejection was treated with high dose of methyl-
prednisolone for 3 d and with OKT3 (muromomab-CD3) if 
the rejection was steroid resistant. After 2007, antithymocyte 
globulin (ATG, Genzyme) replaced OKT3.
HLA Antibody Testing
HLA antibodies were characterized and monitored by 
microbead assay as previously described.15,16 Lymphocyte 
crossmatching was performed at baseline (pretreatment) and 
using a serum sample taken within 24 h pretransplant accord-
ing to our previous description.16
Data Analysis
Patient Survival and Graft Survival
Overall, patient survival and death-censored graft survival 
were analyzed. Patient survival was calculated from the date of 
renal transplantation to date of death or last follow-up. Death-
censored graft survival was calculated from the date of trans-
plantation to the date of graft failure or last follow-up. Graft 
failure was defined as a return to requiring renal replacement 
therapy as indicated in the clinical records of the patients.
Crossmatch Status
Patients were divided into 3 groups: CDC, FC, and Bead 
based on the crossmatch assay on the pretreatment/pretrans-
plant serum samples. If the patients underwent DFPP before 
transplant, pretreatment samples before the start of the first 
DFPP session were used. If not, the pretransplantation serum 
sample was used. One-, 5-, and 10-y graft and patient sur-
vival were analyzed, and outcomes were compared between 
the groups. A further subgroup analysis based on the gender 
was also performed in each of the groups. In the CDC group, 
an analysis was performed based on CDC titer level.
HLA Antibodies
The study subjects were categorized based on their donor-
specific antibody (DSA) status (class I, class II, class I + II 
antibody groups). One-, 5-, and 10-y graft survival outcomes 
between the groups were analyzed.
Rejection
Patients were classified as those who had rejection and 
those who did not based on renal biopsy as described previ-
ously.16 Each case was confirmed by independent review, and 
all cases reported as “suspicious rejection” were included as 
rejection, and comparative 1-, 5-, and 10-y graft survival were 
analyzed. Patients were further categorized based on biopsy-
proven definitive evidence of the type of rejection—AMR, 
T-cell–mediated rejection (TCMR), or mixed rejection,17 and 
the data were reanalyzed retaining only definitive diagno-
sis of rejection with “suspicious rejections” included as no 
rejections.
Further analyses were performed by grouping patients 
based on the number of rejection episodes, that is, no rejec-
tion, 1 episode of rejection, and 2 or more episodes of rejec-
tion. The 1-, 5-, and 10-y graft survivals were compared 
between the 3 groups.
The patients who had rejection were regrouped based on 
the timing of rejection as rejection occurring within the first 
2 wk after transplantation and after the first 2 wk of trans-
plantation. The 1-, 5-, and 10-y graft survivals were compared 
between the 2 groups.
Statistical Analysis
Statistical analysis of comparison between groups was per-
formed with nonparametric testing for interdependent groups 
using IBM SPSS Version 25.0 (SPSS Institute, Chicago, IL). 
Kaplan-Meier death-censored survival analysis was used 
to calculate all survival estimates. Chi-square (Log Rank 
[Mantel-Cox]) was used to determine statistical significance 
in the survival analysis between groups. A probability of val-
ues (P value) <0.05 was considered statistically significant.
RESULTS
A total of 165 consecutive antibody incompatible trans-
plants performed at our unit were reviewed and a final of 134 
was analyzed in this study. Thirty-one patients were excluded 
for the following reasons; 1 patient did not provide consent, 
23 patients had blood group (ABO) incompatibility, or both 
HLA and ABO incompatibility, and 7 did not proceed to 
transplant.
The median follow-up for the HLAi study cohort was 
6.93 ± 3.33 y. The patient and graft survival estimates of our 
HLAi study cohort were compared with (i) first-time deceased 
donor renal transplant, UK cohort, (ii) first-time deceased 
donor transplant, UHCW cohort, and (iii) the standard live 
donor transplant of UHCW cohort from the same time period 
of January 1, 2003 to December 31, 2018, as shown in Table 2. 
There was a significant difference in patient survival between 
the UHCW live donor cohort versus (i) UHCW HLAi cohort 
(P = 0.007), (ii) UK deceased donor cohort (P < 0.001), and 
(iii) UHCW deceased donor cohort (P < 0.001), as shown in 
Figure 1A. Similarly, there was a significant difference in graft 
survival between the UHCW live donor versus (i) UHCW 
HLAi (P = 0.003), (ii) UK deceased donor (P = 0.001), and (iii) 
TABLE 2.
One-, 5-, and 10-y patient and graft survival estimates of 
the different comparative cohorts
Transplant cohorts 
















Total number 134 22 277 441 325
1-y patient survival, % 95.4 99.2 96.8 100
5-y patient survival, % 88.7 97.6 90.4 97.1
10-y patient survival, % 81.1 74.1 80.5 92.7
1-y graft survival, % 95.4 93.6 93.9 98.4
5-y graft survival, % 85.1 85.8 85.2 93.0
10-y graft survival, % 70.2 75.3 75 89.4
HLAi, HLA antibody incompatible; UHCW, University Hospitals Coventry and Warwickshire.
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FIGURE 1. Survival estimates of patients transplanted between January 1, 2003 and December 31, 2018, in the different cohorts—(1) 
HLA incompatible transplants, UHCW (our center) study cohort, (2) first-time deceased donor renal transplant, UK cohort, (3) first-time 
deceased donor transplant, UHCW cohort, and (4) the standard live donor transplant of UHCW cohort. Associated P values were all 
different between the live UHCW donor and all other donor types as given below; however, there were no significant differences between 
other pairs. A, Patient survival: statistically significant difference in patient survival between the UHCW live donor cohort vs (i) UHCW 
HLAi cohort (P = 0.007), (ii) UK deceased donor cohort (P < 0.001), and (iii) UHCW deceased donor cohort (P < 0.001). B, Graft survival: 
statistically significant difference in graft survival between the UHCW live donor vs (i) UHCW HLAi (P = 0.003), (ii) UK deceased donor 
(P = 0.001), and (iii) UHCW deceased donor (P = 0.001). HLAi, HLA antibody incompatible; UHCW, University Hospitals Coventry and 
Warwickshire.
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UHCW deceased donor (P = 0.001), as shown in Figure 1B. 
However, there were no significant differences between other 
pairs in both patient and graft survival.
Antibody Variables Relating to Outcome
Graft Survival
Graft survival was analyzed in term of baseline (immedi-
ately pretreatment) DSA levels characterized by Bead positive 
only, FC positive (Bead+, CDC–), and CDC positive (FC+, 
Bead+). The graft survival for CDC positive group was 83%, 
64%, and 40% at 1, 5, and 10 y, respectively, which is sig-
nificantly lower than the other 2 groups (Bead versus CDC, 
P = 0.007, CDC versus Flow, P = 0.001, and Bead versus Flow, 
P = 0.837) (Figure  2A). The graft survival for FC-positive 
patient group was 100%, 93%, and 77%, and Bead positive 
patient group was 95%, 86%, and 82% at 1, 5, and 10 y, 
respectively.
The graft survival for the 9 female CDC positive patients 
is 75%, 75%, and 30%, which is worse, although not signifi-
cantly different than the 14 male CDC positive patients with 
survival of 87%, 59%, and 47% at 1, 5, and 10 y, respec-
tively (P = 0.572) (Figure 2B). A similar trend was noticed in 
FC-positive and Bead-positive groups in which graft survival 
in females was lower than males, but this did not reach statis-
tical significance.
CDC titer was also seen to influence graft survival 
(Figure  2C). As a group, those with a cytotoxic titer >1 in 
2 did significantly worse than those with a titer at 1 in 2 or 
below. The 1-, 5-, and 10-y graft survival for those with CDC+ 
titer of 1 in 2 or below was 100%, 92%, and 70%, which is 
similar to the CDC negative group and not statistically dif-
ferent. However, the group with a CDC+ titer of >1 in 2 have 
significantly worse outcomes with 1-, 5-, and 10-y survival of 
60%, 30%, and 10% (P < 0.001).
Graft survival was also analyzed with respect to DSA speci-
ficity. The transplants were divided on the basis of antibody 
specificity for donor HLA class I, class II, or both. Although 
there appeared to be poor early graft survival in the group 
with both class I and II DSAs, overall, there is no significant 
difference between these 3 groups (Figure 2D).
Patient Survival
There was no difference in patient survival between the 3 
groups based on DSA levels characterized by Bead positive 
(FC–, CDC–), FC positive (Bead+, CDC–), and CDC posi-
tive (FC+, Bead+). Patient survival for CDC positive females 
FIGURE 2. Graft survival based on (A) pretreatment crossmatch status donor-specific antibody levels according to Bead, Flow, or CDC 
positivity. Significantly reduced graph survival when the baseline crossmatch was CDC positive (Bead vs CDC, P = 0.007; CDC vs Flow, 
P = 0.001; and Bead vs Flow, P = 0.837). B, CDC positivity and gender effect: Within the CDC+ group, overall outcome is poorer for the female 
recipients, although not statistically significant (P = 0.572). C, CDC titers: In those with a CDC+ titer of 1 in 2 or below, graph survival matches the 
CDC negative group. The group with a CDC+ titer of >1 in 2 have significantly worse outcome compared with the low titer group P < 0.001. D, 
Antibody specificity (HLA class type): no difference in graft survival based on class of donor-specific antibodies. Bead, microbead assay; CDC, 
cytotoxic-dependent crossmatch; Flow, flow cytometry crossmatch.
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was lower but not statistically significant at 88%, 63%, and 
63% when compared with males at 100%, 100%, and 83% 
at 1, 5, and 10 y, respectively (P = 0.176) (Figure 3). There was 
a similar trend in the FC-positive and Bead-positive groups 
with lower survival in the females but not reaching statistical 
significance. There was also no difference in patient survival 
based on CDC titer or antibody specificity to HLA class (I, II, 
or I+II).
Rejection on Graft Survival Outcomes
The 1-, 5-, and 10-y graft survival for patients who had 
rejection was 93%, 77%, and 54% when compared with 
those who did not have rejection which was 97%, 91%, and 
82%. This was statistically significant, P = 0.002.
Of 80 cases that were crossmatch positive (Flow or CDC) 
preplasmapheresis (DFPP), 48 cases were flow crossmatch 
positive at pretransplant analyses. There was no increased 
rejection based on flow crossmatch positivity in this group 
(P = 0.26, Fisher Exact 2-tailed test). However, higher rela-
tive median frequency on flow cytometry was associated 
with increased rates of rejection (Mann-Whitney analysis 
P = 0.024). A higher median RMF would relate to higher total 
DSA MFI values.
Type of Rejection
Fifty-seven patients had any type of rejection diagnosed 
by biopsy, including “suspicious” (Table 3). Of these, 47 had 
AMR with 1-, 5-, and 10-y graft survival of 91%, 77%, and 
49%, which is significantly lower than those with no rejec-
tion, P < 0.001. The graft survival of patients with TCMR was 
87% at 1, 5, and 10 y with no significant difference in overall 
graft survival when compared with patients who had no rejec-
tion, P = 0.97(Table 3 and Figure 4A). Although the estimated 
graft survival of patients with mixed rejection is comparable 
to AMR, as the numbers were low this did not reach statistical 
significance. The analysis was repeated including only defini-
tive diagnosis of biopsy-proven rejection, and the results were 
similarly statistically significant, although 10-y graft survival 
of AMR was lower at 39% (data not shown).
Number of Rejection Episodes
As the number of rejection episodes increases, the graft sur-
vival decreases. When there was a single rejection episode, the 
graft survival rates are 95%, 82%, and 67% and with 2 or 
more rejection episodes it was 85%, 61%, and 15% at 1, 5, 
and 10 y, respectively. This is significantly lower compared 
with patients who had a single episode (P = 0.003) and those 
who had no rejection (P < 0.001) (Figure 4B and Table 3). The 
results are similar when the data were reanalyzed including 
only definitive diagnosis of rejection as rejection episodes.
Timing of Rejection
Rejection occurring only within the first 2 wk of transplan-
tation did not cause any significant decline in the long-term 
graft survival when compared with rejection-free patients 
with rates of 97%, 91%, and 82% at 1, 5, and 10 y, P = 0.95. 
In contrast, graft survival was significantly lower in those with 
rejection occurring for the first time after 2 wk (P < 0.001) 
FIGURE 3. Effect of cytotoxic-dependent crossmatch positivity and gender on patient survival. Patient survival for cytotoxic-dependent 
crossmatch positive females was lower at 88%, 63%, and 63% at 1, 5, and 10 y, respectively when compared with males, P = 0.176.
TABLE 3.






Not within total that 
had graft failure 1 y 5 y 10 y
Total number 134 30 95.4 85.1 70.2
No rejection 77 17 97 91 82
Antibody-mediated rejection 47 14 91 77 49
Cellular rejection (TCMR) 8 1 87 87 87
Mixed rejection 2 1 100 50 50
Within the first 2 wk 29 2 97 97 79
After the first 2 wk 19 9 84 49 27
Within and after the first 2 wk 9 5 89 78 31
1 rejection episode 44 7 95 82 67
2 or more rejection episodes 13 9 85 61 15
TCMR, T-cell–mediated rejection.
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or continuing to occur after the first 2 wk of transplantation 
(P < 0.001) compared with rejection-free patients. The 1-, 5-, 
and 10-y graft survival for patients who had rejection after 
the first 2 wk of transplantation was 84%, 49%, and 27%, 
and for those who had rejection within and after 2 wk this 
was 89%, 78%, and 31%. There was a significant difference 
FIGURE 4. Graft survival based on (A) rejection types: the graft survival in antibody-mediated rejection was 91%, 77%, and 49% when 
compared with rejection-free patients with survival of 97%, 91%, and 82% at 1, 5, and 10 y (P < 0.001). B, Number of rejection episodes: If 2 or 
more rejection episodes the graft survival rate were significantly lower, P < 0.001 if no rejection and P = 0.003 if 1 episode of rejection. C, Timing 
of rejection: if rejection occurred or continued to occur after 2 wk, the graft survival was significantly lower, P < 0.001. tx, transplant.
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in the graft survival estimates for patients who had rejection 
in <2 wk posttransplant when compared with those who had 
rejection after 2 wk (P < 0.001) and for those who had rejec-
tion episodes within and after the first 2 wk of transplanta-
tion (P = 0.003) (Figure 4C and Table 3). The results were also 
similar when the data were reanalyzed including only defini-
tive diagnosis of rejection as rejection episodes.
DISCUSSION
There has been a lack of published, long-term outcome 
data for HLAi renal transplantation and we have addressed 
this. The patient and graft survival estimates of our HLAi 
cohort for 1, 5, and 10 y is 95%, 90%, and 81% and 95%, 
85%, and 70%, respectively. This is similar to the outcomes 
seen for first time, deceased brain dead donor transplants in 
the United Kingdom18 and at our center for the same time 
period. However, there was a significant difference in overall 
patient and graft survival between the HLAi study cohort and 
the standard live donor transplant cohort at our center. Given 
the higher risk nature of our cases, more than half of whom 
had repeat transplants, this report provides reassurance that 
HLAi transplantation can, overall, offer good long-term out-
comes for highly sensitized patients with a low prospect of a 
compatible donor.
We have looked in detail at 2 factors that significantly affect 
outcome: measurements of baseline sensitization and the 
nature of the rejection responses. Graft survival for the group 
with a positive baseline CDC crossmatch is significantly lower 
when compared with the FC- and Bead-positive groups. This 
association between cytotoxic reactivity against donor HLA 
and poor outcome is now well described.11,12,18-21 However, in 
our experience, it is only the higher levels of cytotoxic reac-
tivity, that is CDC titer >1 in 2 that determine reduced graft 
survival. The graft survival of the CDC low titer group was 
similar to the CDC negative group. This observation therefore 
should widen access to transplantation to almost half of cases 
referred with a positive CDC crossmatch who might other-
wise be declined.
We did not find any statistical differences in death-censored 
graft survival when comparing cases with either HLA class I, 
class II, or both class I and II DSAs. It has been shown that 
patients with complement fixing HLA class I DSAs had infe-
rior graft survival compared with HLA class II DSAs.22 On 
looking at our data further, we noted an unexpected distribu-
tion (P < 0.001) of DSA types between the crossmatch cases, 
with a clear bias towards combined class I and II DSAs in the 
patients with a positive CDC crossmatch (data not shown). 
There were 12 graft losses in the CDC+ group and the earliest 
5 (4 within 1 y) were in patients with both class I and II DSAs. 
It might be that the reaction complexity of the sera enhances 
complement activation on donor cells, and this might not be 
so apparent using single antigen capture assays to character-
ize complement activation. The CDC test has the advantage 
that it is directly donor-specific, however, it is not a standard-
ized test. We do not use the more sensitive antihuman globulin 
enhanced method and therefore our baseline measurements 
of overall reactivity would represent higher levels compared 
with results using the enhancement approach.
We also saw a trend in which female recipients with DSAs 
had poorer graft and patient survival compared with male 
recipients. Although consistent with our previous observations 
that pregnancy stimulated DSAs rebound more aggressively 
in this cohort,23 this does not reach statistical significance. 
Studies in pregnancy have shown an anti-inflammatory state 
in pregnancy with an increase in the T helper 2 cytokines and 
immune modulatory proteins with a shift postpartum.24,25 
It could be speculated that the proinflammatory state post-
partum in general and increased sensitivity to pregnancy 
induced antigens specifically, could result in decreased graft 
and patient survival. The relationship between pregnancy and 
subsequent HLAi transplantation needs further study because 
the consequences seem severe.
AMR was the only rejection type that significantly reduced 
graft survival in comparison to TCMR or no rejection in our 
study. We see graft survival estimates of 49% at 10 y if there 
was an occurrence of definitive or suspicious AMR, compared 
with 82.4% if there was no rejection. Conversely, TCMR in 
HLAi transplantation, though there were relatively low num-
bers in our study, seems to be more amenable to successful 
treatment and does not necessarily precipitate graft loss. Our 
analysis extends the time frame and is consistent with find-
ings from similar studies showing significantly lower 5-y graft 
survival in patients who had AMR.26,27
Finally, we have made the observation that the timing of 
an early rejection episode, either side of 2 wk posttransplant, 
is significant in terms of short and long-term graft survival. 
No significant difference was observed in graft survival prob-
ability between patients who only had rejection within the 
first 2 wk following transplantation and those who had no 
rejection at all. However, there was a significant impact on 
graft survival if rejection occurred after the first 2 wk of trans-
plantation or within and after the first 2 wk of transplanta-
tion. In addition, experiencing >1 rejection episode caused 
a significant reduction in graft survival rates in our study. 
This latter finding has been shown before in standard trans-
plants.28 In our cohort, the majority of transplants with >1 
rejection episode experienced an event both within and after 
2 wk from transplantation. Several factors could contribute to 
these observations in HLAi transplantations. Intensive moni-
toring of patients during the first few wk following transplan-
tation, could detect rejection early, resulting in prompt and 
efficient management.29 Whereas, rejection occurring later on 
is often diagnosed when patients present with overt symptoms 
or upon routine checkup. Interestingly, we observed that of 
the patients who experienced 2 or more rejection episodes, 
the majority were those with rejections occurring within and 
after the first 2 wk of transplantation and was therefore asso-
ciated with nonresolution of the first episode. AMR is con-
sidered to be a disease process with a continuum of severity, 
beginning at any time after transplantation and developing at 
varying levels of intensity, progressively leading to the devel-
opment of chronic allograft damage, dysfunction, and loss.30 
However, we found significantly better outcomes in those 
with the earlier, compared with those with later rejection epi-
sodes. Thus, the earlier rejections seem to be more effectively 
treated, for operational reasons, as above, or perhaps because 
of fundamental immunologic reasons, thereby limiting AMR 
progression.
STRENGTHS AND LIMITATIONS
This is a study from a tertiary international referral center 
for HLAi renal transplantation in the United Kingdom. As 
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our unit has considerable experience in such transplantations, 
these results may not necessarily be extrapolated to other 
practices. Also, the number of cases is limited given the con-
straints of a single center. As it is a retrospective study, the 
protocols were not standardized, which could have resulted in 
a bias in the outcomes.
This is the first long-term study of a relatively large cohort 
of HLAi transplants that shows equivalent graft and patient 
survival to deceased donor transplantation. We have identified 
2 key areas that allow very good outcomes in what is consid-
ered high-risk transplantation. Exclusion of the highest immu-
nologic risk cases, defined as those with a CDC titer of >1 in 
2, gives us an estimated 10-y graft survival of almost 75%. 
Similarly, those with AMR or TCMR diagnosed and treated 
within the first 2 wk posttransplantation can be expected to 
have a good chance of long-term transplant survival.
CONCLUSIONS
Long-term graft and patient survival for HLAi renal 
transplantation is similar to deceased donor transplanta-
tion. There are certain subgroups, in particular those with 
a crossmatch CDC titer of >1 in 2, antibody-positive female 
patients, and unresolving or recurrence of AMR, which are 
associated with a poor prognosis. Given that the need for 
HLAi transplantation exists and is likely to increase in the 
future, despite PKE programs, further large studies looking 
at risk stratification, early diagnosis, and management of 
rejection are needed.
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